Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmonary function, airway resistance and bronchodilator treatment in pulmonary hypertension
ChiCTR2200063362Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of indacaterol + glycopyrronium in pulmonary hypertension (PH) and airway diseases (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: mMRC score, six-minutes walk distance and 3 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
pulmonary hypertension (PH)airway diseases
Beyond the preview
Go deeper on ChiCTR2200063362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063362.